BioRestorative Therapies (BRTX) executive compensation, 2025 proxy

Lance Alstodt, Chief Executive Officer, was paid $1.3M in 2024, up 5% from $1.3M the year before.

Filed
August 8, 2025
Annual meeting
September 18, 2025
Pay year
2024
Named executives
3
CEO total pay
$1.3M+5% vs prior year
CEO compensation actually paid
$1,202,070After equity award adjustments
CEO equity adjustment
$387,487For 2024
Average non-CEO NEO total
$955,4182024 average
CEO option awards
$500,0002024 grant-date fair value
Company TSR
$32.95Value of $100 investment
Net loss
$8,979,3812024 net loss

How Alstodt was paid

$1.3M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary41%Bonus21%Option awards38%

Named executive officers

ExecutiveTotal
Lance AlstodtChief Executive Officer$1,314,583
Francisco SilvaVP, Research and Development$1,227,083
Robert KristalChief Financial Officer$683,752

What changed and why

  • $1.3M$1,314,583 was the CEO's 2024 total compensation, including $500,000 in option awards and a $275,000 bonus.
  • $1.2M$1,202,070 was the CEO's 2024 compensation actually paid after $387,487 in equity award adjustments.
  • $955K$955,418 was the 2024 average total compensation for non-CEO named executive officers.
  • $275K$275,000 was the CEO's discretionary 2024 bonus, paid in 2025.
  • $450K$450,000 was Francisco Silva's 2024 option award value, compared with $300,000 in 2023.
  • $32.95$32.95 was the Company's 2024 value of an assumed $100 investment, while net loss was $8,979,381.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.